Primaquine therapy for malaria

Clinical Infectious Diseases

Volumn 39, Issue 9, 2004, Pages 1336-1345

  Baird, J Kevin ^a   Hoffman, Stephen L ^b  

^a California   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; PRIMAQUINE; PROGUANIL;

ABDOMINAL CRAMP; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ENDEMIC DISEASE; GASTROINTESTINAL TOXICITY; GEOGRAPHY; HEMOLYTIC ANEMIA; HUMAN; MALARIA; METHEMOGLOBINEMIA; NAUSEA; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; RELAPSE; REVIEW;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; HUMANS; MALARIA; PLASMODIUM; PRIMAQUINE;

EID: 7644226738     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424663     Document Type: Review

References (114)

1. World Health Organization (WHO). Fact sSheet no. 94. Geneva: WHO, 1996.
2. Zucker JR. 1996. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerging Infect Dis 1996; 2:37-43.
3. Baird JK. Malaria at the millennium: control strategies in crisis. Drugs 2000; 59:719-43.
4. Centers for Disease Control and Prevention. Local transmission of Plasmodium vivax malaria-Houston, Texas, 1994. MMWR Morb Mortal Wkly Rep 1995;44 (15):301-3.
5. Layton LM, Parise ME, Campbell CC, et al. Mosquito-transmitted malaria in New York City, 1993. Lancet 1995; 346:729-31.
6. Brooke JH, Genese CA, Bloland PB, Zucker JR, Spitalny KC. Probable introduced malaria transmission in New Jersey. N Engl J Med 1994; 331:22-3.
7. Centers for Disease Control and Prevention. Mosquito-transmitted malaria-California and Florida, 1990. MMWR Morb Mortal Wkly Rep 1990;40 (6):106-8.
8. Coatney GR, Collins WE, Warren McW, Contacos PG. The primate malarias. Bethesda, MD: US Department of Health, Education and Welfare, National Institutes of Health, 1971.
9. Rieckmann KH, McNamara JV, Kass L, Powell RD. Gametocytocidal and sporonticidal effects of primaquine upon two strains of Plasmodium falciparum. Military Med 1969; 134:802-19.
10. Garnham PCC. Hypnozoites and "relapses" in Plasmodium vivax and in vivax-like malaria. Trop Geogr Med 1988; 40:187-95.
11. Most H, London IM, Kane CA, Lavietes PH, Shroeder EF, Hayman JM Jr. Chloroquine for treatment of acute attacks of vivax malaria. JAMA 1946; 131:963-7.
12. Alving AS, Hankey DD, Coatney GR, et al. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 1953; 6:970-6.
13. Hankey DD, Jones Jr R, Coatney GR, et al. Korean vivax malaria. I. Natural history and response to chloroquine. Am J Trop Med 1953; 2:958-69.
14. Coatney GR, Alving AS, Jones R Jr, et al. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg 1953; 6:985-88.
15. Adak T, Sharma VP, Orlov VS. Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg 1998; 59:175-9.
16. Sharma RC, Gautam AS, Orlov V, Sharma VP. Relapse pattern of Plasmodium vivax in Kheda District, Gujarat. Indian J Malariol 1990; 27:95-9.
17. Wiselogle FY. A survey of antimalarial drugs: 1941-1945. 2 vols. Ann Arbor, Ml: J.W. Edwards, 1943.
18. Edgcomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L. Primaquine, SN 13272: a new curative agent in vivax malaria: a preliminary report. J National Malaria Soc 1950; 9:285-92.
19. Fairlely NH. Chemotherapeutic suppression and prophylaxis in malaria. Trans Roy Soc Trop Med Hyg 1945; 38:311-57.
20. Most H, London IM, Kane CA, Lavietes PH, Schroeder EF, Hayman JM Jr. Chloroquine for treatment of acute attacks of vivax malaria. JAMA 1946; 131:963-7.
21. Gordon HH, Dieuaide FR, Marble A, Christianson HB, Dahl LK. Treatment of Plasmodium vivax of foreign origin. Arch Int Med 1947; 79:365-81.
22. Sinha S, Dua VK, Sharma VP. Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at BHEL Industrial Complex, Hadwar (U.P.). Indian J Malariol 1989; 26:83-6.
23. Rowland M, Durrani N. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans Roy Soc Trop Med Hyg 1999; 93:641-3.
24. Luxemburger C, van Vugt M, Jonathan S, et al. Treatment of vivax malaria on the western border of Thailand. Trans Roy Soc Trop Med Hyg 1999; 93:433-8.
25. Schwartz E, Sidi Y. New aspects of malaria imported from Ethiopia. Clin Infect Dis 1998; 26:1089-91.
26. Ohtomo H, Hioki A, Tanabe K, Nakabayashi T, Ishizaki T. Clinical evaluation of antimalarial regimens in Japan. Zbl Bakt Hyg A 1987; 264:513-20.
27. Ehrman FC, Ellis JM, Young MD. Plasmodium vivax Chesson strain. Science 1945; 101:377.
28. Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997; 56:621-6.
29. Smoak BL, DeFraites RF, Magill AJ, Kain KC, Wellde BT. Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 1997; 56:231-4.
30. Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria-implications for chemoprophylaxis in travelers. New Engl J Med 2003; 349:1501-6.
31. Carson PE. 8-Aminoquinolines. In: Peters W, Richards WHG, eds. Antimalarial drugs. II. Current antimalarials and new drug developments. Berlin: Springer-Verlag, 1984:83-121.
32. Schmidt LH, Fradkin R, Vaughan D, Rasco J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg 1977 26:1116-28.
33. Clyde DF, McCarthy VE. Radical cure of chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 1977; 26:562-3.
34. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull WHO 1960; 22:621-31.
35. Brueckner RP, Ohrt C, Baird JK, Milhous WK. 8-Aminoquinolines. In: Rosenthal PJ, ed. Antimalarial chemotherapy: mechanisms of action, resistance and new directions in drug discovery. Totowa, NJ: Humana Press, 2000:123-51.
36. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bull WHO 1981; 59:391-5.
37. Palmer RMJ, Weatherall M. The effect of some anti-inflammatory and antimalarial drugs on the migration of horse leukocytes in vitro. Br J Pharmacol 1977; 59:472.
38. Thong YH, Ferrante A, Rowan-Kelly B. Primaquine inhibits mitogen-induced human lymphocyte proliferative responses. Trans Roy Soc Trop Med Hyg 1978; 72:537-9.
39. Thong YH. Immunosuppression caused by primaquine. Trans Roy Soc Trop Med Hyg 1979; 73:474.
40. Thong YH, Ferrante A, Seeker LK. Normal immunological responses in mice treated with chloroquine, quinine and primaquine. Trans Roy Soc Trop Med Hyg 1981; 75:108-9.
41. Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1955; 46:301-6.
42. Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995; 171:1678-82.
43. Fryauff DJ, Richards AL, Baird JK, et al. Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis. Antimicrob Agents Chemother 1996; 40: 2737-42.
44. Fryauff DJ, Baird JK, Purnomo, et al. Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Am J Trop Med Hyg 1997; 56:137-40.
45. Kaplan MH, Bernstein LS. Improved therapy for Vietnam acquired vivax malaria. Military Med 1974:444-8.
46. Bunnag D, Karbwang J, Thanavibul A, et al. High dose primaquine in primaquine resistant vivax malaria. Trans Roy Soc Trop Med Hyg 1994; 88:218-9.
47. Pukrittayakamee S, Vanijononta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169:932-5.
48. Saint-Yves IFM. Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands. P N G Med J 1977; 20:62-5.
49. Alving AS, Hankey DD, Coatney R, et al. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 1953; 6:970-6.
50. Coatney GR, Alving AS, Jones R Jr, et al. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg 1953; 6:985-8.
51. Thaeler AD, Arnold JD, Alving AS. A clinical study of primaquine (SN-13272) in the treatment of malaria among the Miskito Indians of Nicaragua. Am J Trop Med Hyg 1953; 2:989-99.
52. Miller LH, Wyler DJ, Glew RH, Collins WE, Contacos PG. Sensitivity of four Central American strains of Plasmodium vivax to primaquine. Am J Trop Med Hyg 1974; 23:309-10.
53. Martelo OJ, Smoller M, Saladin TA. Malaria in American soldiers. Arch Intern Med 1969; 123:383-7.
54. Fisher GU, Gordon MP, Lobel HO, Runcik K. Malaria in soldiers returning from Vietnam: epidemiologic, therapeutic and clinical studies. Am J Trop Med Hyg 1970; 19:27-39.
55. Boulos M, Amato Neto V, Dutra AP, Di Santi SM, Shiroma M. Analise da frequencia de recaidas de malaria por Plasmodium vivax em regiao nao endemica. Rev Inst Med Trop Sao Paulo 1991; 33:143-6.
56. Kass MA, Gordon M, Morley RE, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103: 188-93.
57. Tanabe K, Shimada K. Clinical evaluation of antimalarial drugs [in Japanese]. Kansenshogaku Zasshi 1990; 64:668-73.
58. Roth HP, Caron HS. Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther 1978; 23:361-70.
59. Jelinek T, Nothdurft HD, Von Sonnenburg F, Loscher T. Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg 1995; 52:322-4.
60. Ronn AM, Bygbjerg IC. Problemer med primakin-recidivprofylakse hos malariapatienter. Ugeskr Laeger 1993; 155:3901-4.
61. Isaac-Renton JL, Koon ALK, Chan RMT, Chow AW, Sacks SL. Drug resistance in malaria: three cases and a review. Can Med Assoc J 1983; 129:454-7.
62. Henderson A, Simon J, Melia W, Navein J, McCallum J. Polyresistant malaria in Ghurka soldiers returning from Papua New Guinea: treatment and prevention. J R Army Med Corps 1986; 132:37-41.
63. Rombo L, Edwards G, Ward SA, et al. Seven patients with relapses of Plasmodium vivax or P. ovale despite primaquine treatment. Trop Med Parasitol 1987; 38:49-50.
64. Charoenlarp P, Harinasuta T. Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases. Southeast Asian J Trop Med Public Health 1973; 4:135-7.
65. Luzzi GA, Warrell DA, Barnes AJ, Dunbar EM. Treatment of primaquine-resistant Plasmodium vivax malaria [letter]. Lancet 1992; 340:310.
66. Lapierre J, Coquelin B, Galal AA, et al. Chimioresistance de souches de Plasmodium falciparum et Plasmodium vivax au Combodge particularites morphologiques de Plasmodium vivax. Medecine Tropicale 1984; 44:339-49.
67. Arias AE, Corredor RA. Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy. Trop Med Parasitol 1988; 40:21-3.
68. Looareesuwan S, Wilairatana P, Glanarongran R, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax in Thailand. Trans Roy Soc Trop Med Hyg 1999; 93:637-40.
69. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 2001; 65:471-6.
70. Schwartz E, Regev-Yochay G, Kurnik D. Considering primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 2000; 62:393-5.
71. Arnold J, Alving AS, Clayman CB, Hochwald RS. Induced primaquine resistance in vivax malaria. Trans Roy Soc Trop Med Hyg 1961; 55: 345-50.
72. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistant to chloroquine? Lancet 1989; 2:1183-4.
73. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44:547-52.
74. Murphy GS, Basri H, Purnomo, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341:96-100.
75. Phillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax acquired in Guyana, South America. Clin Infect Dis 1996; 23:1171-3.
76. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996; 55:243-9.
77. Singh J, Ray AP, Misra BG, Nair CP. Antirelapse treatment with primaquine and pyrimethamine. Indian J Malariol 1954; 8:127-36.
78. Basavaraj HR. Observations on the treatment of 678 malaria cases with primaquine in an area free from malaria transmission in Mysore State, India. Indian J Malariol 1960; 14:269-81.
79. Contacos PG, Coatney GR, Collins WE, Briesch PE, Jeter MH. Five day primaquine therapy: an evaluation of radical curative activity against vivax malaria infection. Am J Trop Med Hyg 1973; 22:693-5.
80. Cedillos RA, Warren M, Jeffery GM. Field evaluation of primaquine in the control of Plasmodium vivax. Am J Trop Med Hyg 1978; 27: 466-72.
81. Roy RG, Shanmugham CAK, Chakrapani KV, Ganeshan AV. Results of 5 day course of radical treatment of Plasmodium vivax in six districts of Tamil Nadu. Indian J Med Res 1979; 69:939-43.
82. Singh N, Mishra AK, Sharma VP. Radical treatment of vivax malaria in Madhya Pradesh, India. Indian J Malariol 1990; 27:55-6.
83. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA. Efficacies of 5-and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 1999; 93:809-12.
84. Yadav RS, Ghash SK. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. J Parasitol 2002; 88:1042-4.
85. Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira-da-Silva LH. In vivo sensitivity of Plasmodium vivax isolates from Rondonia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Ann Trop Med Parasitol 2000; 94:749-58.
86. Prasad RN, Virk KJ, Sharma VP. Relapse/reinfection patterns of Plasmodium vivax infection: a four year study. Southeast Asian J Trop Med Public Health 1991; 22:499-503.
87. Dua VK, Sharma VP. Plasmodium vivax relapses after 5 days of primaquine treatment in some industrial complexes of India. Ann Trop Med Parasitol 2001; 95:655-9.
88. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169:932-5.
89. Wilairatana P, Silachamroon U, Krudsood S, et al. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax in Thailand. Am J Trop Med Hyg 1999; 61:973-7.
90. Baird JK, Wiady I, Sutanihardja A, et al. Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 2002; 66:659-60.
91. Arnold J, Alving AS, Hockwald RS, et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria. J Lab Clin Med 1955; 46:391-7.
92. Rieckmann KH, McNamara JV, Frischer H, Stocken TA, Carson PE, Powell RD. Gametocytocidal and sporonticidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull WHO 1968; 38:625-32.
93. Rieckmann KH, McNamara JV, Kass L, Powell RD. Gametocytocidal and sporonticidal effects of primaquine upon two strains of Plasmodium falciparum. Military Medicine 1969; 134:802-19.
94. Hogh B, Gamage-Mendis A, Butcher GA, et al. The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector. Am J Trop Med Hyg 1998; 58:176-82.
95. Gogtay NJ, Chogle AR, Sorabjee JS, Marathe SN, Kshirsagar NA. Poor gametocytocidal activity of 45 mg primaquine in chloroquine-treated patients with acute, uncomplicated Plasmodium falciparum malaria in Mumbai (Bombay): an issue of public health importance. Ann Trop Med Parasitol 1999; 93:813-6.
96. Kaneko A, Kamei K, Suzuki T, Ishii A, Siagian R, Panjaitan W. Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health 1989; 20:351-9.
97. Klein TA, Tada MS, Lima JBP, Tang AT. Infection of Anopheles darlingi fed on patients infected with Plasmodium vivax before and during treatment with chloroquine plus primaquine in Costa Marques, Rondonia, Brazil. Mem Inst Oswaldo Cruz 1992; 87:191-5.
98. Baird JK, Purnomo, Masbar S. Plasmodium ovale in Indonesia. Southeast Asian J Trop Med Pub Health 1990; 21:541-4.
99. Patterson JE, Bia FJ, Miller K, McPhedran P. Relapsing malaria infection acquired in Kenya. Yale J Biol Med 1987; 60:245-53.
100. Purnomo, Solihin A, Gomez-Saladin E, Bangs MJ. Rare quadruple malaria infection in Irian Jaya Indonesia. J Parasitol 1999; 85:574-9.
101. Nathwani D, Currie PF, Smith CC, Khaund R. Recurrent Plasmodium ovale infection from New Guinea-chloroquine resistance or inadequate primaquine therapy. J Infect 1991; 23:343-4.
102. Brewer GJ, Tarlov AR, Alving AS. The toxicity of the 8-aminoquinoline antimalarial drugs. Bull Nat Soc Ind Mal Mosq Dis 1961; 9:331.
103. Clayman CB, Arnold J, Hochwald RS, Yount EH, Edgcomb JH, Alving AS. Toxicity of primaquine in Caucasians. JAMA 1952; 149:1563-8.
104. Fryauff DJ, Baird JK, Basri H, et al. Randomized placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346:1190-3.
105. Weiss WR, Johnson A, Oloo AJ, Hoffman SL. Daily primaquine is an effective prophylaxis against falciparum malaria in Kenya. J Infect Dis 1995; 171:1569-75.
106. Baird JK, Fryauff DJ, Basri H, et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hygiene 1995; 52:479-84.
107. Fletcher KA, Evans-Price DA, Giles HM, et al. Studies on the pharmacokinetics of primaquine. Bull WHO 1981; 59:407.
108. Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia: treatment issues. Drug Safety 1996; 14:394.
109. Hall AH, Kulig KW, Rumack BH. Drug- and chemical-induced methaemoglobinaemia: clinical features and management. Medical Toxicol 1986; 81:579-82.
110. Beutler E. G6PD deficiency. Blood 1994; 84:3613-36.
111. Baird JK, Davidson DE, Decker-Jackson JE. Oxidative activity of hydroxylated primaquine analogs: non-toxicity to glucose-6-phosphate dehydrogenase-deficient human red blood cells in vitro. Biochemical Pharmacology 1986; 35:1091-8.
112. Echler G. Determination of glucose-6-phosphate dehydrogenase. Am J Med Technol 1983; 49:259.
113. Tantular IS, Iwai K, Lin K, et al. Field trials of a rapid test for G6PD deficiency in combination with a rapid diagnosis of malaria. Trop Med Int Health 1999; 4:245-50.
114. Baird JK, McCormick GJ, Canfield CJ. Effects of nine synthetic putative metabolites of primaquine on activity of the hexose monophosphate shunt in human red blood cells in vitro. Biochem Pharmacol 1986; 35:1099-106.